In a 66‑year‑old female with major depressive disorder (recurrent, moderate), generalized anxiety disorder, insomnia, dysarthria and cognitive deficits following cerebral infarction, who is taking escitalopram 5 mg daily, mirtazapine 15 mg at bedtime, trazodone 100 mg at bedtime, memantine 5 mg daily, and cholecalciferol 5000 IU daily, and reports persistent trouble sleeping after an ineffective trial of cognitive‑behavioral therapy, what safe pharmacologic intervention can be used to improve her sleep?

Increase Mirtazapine Dose to 30 mg at Bedtime

Given that this patient is already on mirtazapine 15 mg at bedtime with persistent insomnia despite CBT-I, the most evidence-based and safest intervention is to increase the mirtazapine dose to 30 mg at bedtime. This approach leverages an existing medication with established efficacy for both depression and insomnia, while avoiding polypharmacy and additional drug interactions in a patient with cognitive deficits post-stroke 1, 2.

Rationale for Dose Escalation

Mirtazapine demonstrates a paradoxical dose-response relationship for sedation—lower doses (7.5-15 mg) primarily block histamine H1 receptors causing sedation, while higher doses (30-45 mg) increasingly engage noradrenergic and serotonergic mechanisms that can reduce sedative effects but improve overall antidepressant and anxiolytic efficacy 3, 2. However, at 30 mg, sufficient H1 blockade typically persists to maintain sleep-promoting effects while providing superior antidepressant and anti-anxiety benefits 1, 2.

Recent evidence shows:

• In MDD patients with insomnia, mirtazapine achieved 62.4% insomnia remission and 41.3% depression remission by day 42 at mean doses of 18.7 mg/day 1
• Mirtazapine significantly improved all quality of life domains, with the greatest improvements in physical and psychological domains 1
• The medication was well-tolerated with the most common side effects being increased appetite, drowsiness, and weight gain—effects already being monitored in your patient 1

Why Not Add Another Agent?

Adding eszopiclone or zolpidem would be premature given:

1. Drug interaction concerns: The patient is already on trazodone 100 mg HS. The FDA label explicitly warns against combining mirtazapine with benzodiazepines and advises caution with other CNS depressants 4. Adding a Z-drug would create triple sedative therapy (mirtazapine + trazodone + Z-drug), substantially increasing fall risk, cognitive impairment, and respiratory depression—particularly dangerous in a 66-year-old with existing cognitive deficits post-stroke.

2. Guideline recommendations: The American College of Physicians guidelines show that while eszopiclone and zolpidem improve short-term sleep outcomes, evidence in older adults is limited, and observational studies link hypnotics to increased dementia, fractures, and major injury 5. Your patient already has cognitive deficits (I69.318, R41.841), making her particularly vulnerable.

3. Existing sedative load: She's already on trazodone 100 mg HS, which provides serotonergic sleep promotion. Before adding another agent, optimize what's already prescribed.

Alternative: Consider Reducing or Discontinuing Trazodone

If increasing mirtazapine to 30 mg doesn't adequately improve sleep within 2-3 weeks, consider tapering trazodone while maintaining mirtazapine 30 mg. Rationale:

• Trazodone at 100 mg may provide insufficient sleep benefit while contributing to polypharmacy 6
• The Cochrane review found only modest evidence for trazodone in insomnia (SMD -0.34), with common adverse effects including morning grogginess 6
• Mirtazapine at 30 mg may provide superior combined antidepressant, anxiolytic, and sleep-promoting effects as monotherapy 2, 7
• Reducing medication burden may improve cognitive function post-stroke

If Mirtazapine Optimization Fails

Only after optimizing mirtazapine (and potentially simplifying by removing trazodone) should you consider adding a hypnotic. If additional pharmacotherapy becomes necessary, eszopiclone 1-2 mg would be the evidence-based choice 5, 8, 9:

• Moderate-quality evidence supports eszopiclone for improving sleep in older adults 8
• Eszopiclone combined with escitalopram (an SSRI similar to your patient's escitalopram) improved both sleep and anxiety in GAD patients without tolerance over 8 weeks 9
• Start at 1 mg in older adults to minimize adverse effects 5

Critical Safety Monitoring

Given this patient's post-stroke cognitive deficits and multiple CNS-active medications:

• Monitor for increased fall risk with any dose changes—mirtazapine causes orthostatic hypotension and sedation 4
• Assess for serotonin syndrome given the combination of escitalopram, mirtazapine, and trazodone (all serotonergic agents) 4, 10
• Watch for QT prolongation—both mirtazapine and trazodone carry this risk, particularly in combination 4, 10
• Evaluate cognitive function at follow-up, as excessive sedation could worsen existing deficits
• Monitor weight and metabolic parameters—mirtazapine commonly causes weight gain and increased lipids 4

Implementation Algorithm

1. Week 0: Increase mirtazapine from 15 mg to 30 mg at bedtime; continue all other medications
2. Week 2-3: Assess sleep improvement, tolerability, and side effects
3. If inadequate response: Consider tapering trazodone by 25-50 mg every 5-7 days while maintaining mirtazapine 30 mg
4. If still inadequate after 4-6 weeks: Add eszopiclone 1 mg at bedtime (after discussing risks/benefits given age and cognitive status)
5. Throughout: Monitor falls, cognition, mood, anxiety, and metabolic parameters

This stepwise approach prioritizes medication optimization before polypharmacy expansion, directly addresses the patient's quality of life through improved sleep, and minimizes mortality risk from falls and cognitive decline in a vulnerable older adult with cerebrovascular disease.